Balancing the benefits and costs of colony-stimulating factors: a current perspective.

[1]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Terrin,et al.  Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors , 2003, Supportive Care in Cancer.

[3]  M. Piccart,et al.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  G. Lyman,et al.  Filgrastim in Patients with Neutropenia , 2002, Drugs.

[5]  G. Lyman,et al.  PCN12 AN UPDATED RISK THRESHOLD MODEL FOR G-CSF PROPHYLAXIS USE IN CANCER CHEMOTHERAPY: INCORPORATION OF PATIENT OUT-OF-POCKET AND INDIRECT COSTS , 2002 .

[6]  G. Lyman,et al.  Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. , 2002, The American journal of medicine.

[7]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Ruth E. Brown,et al.  Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature , 2001 .

[9]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Lyman.  A Predictive Model for Neutropenia Associated with Cancer Chemotherapy , 2000, Pharmacotherapy.

[11]  T. Intragumtornchai,et al.  A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma , 2000, Leukemia & lymphoma.

[12]  G. Lyman,et al.  The economics of febrile neutropenia: implications for the use of colony-stimulating factors. , 1998, European journal of cancer.

[13]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[14]  D. Smink,et al.  Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Vries,et al.  Dose intensity of standard adjuvant cmf with G-CSF for premenopausal node-positive breast cancer patients. , 1998 .

[16]  E. D. de Vries,et al.  Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. , 1996, Oncology.

[17]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[18]  C Sebban,et al.  Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Lyman,et al.  Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. , 1993, Journal of the National Cancer Institute.

[20]  J. von Pawel,et al.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. , 1993, European journal of cancer.

[21]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[22]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[23]  D Faraggi,et al.  Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables , 1990, Cancer.

[24]  R A Olshen,et al.  Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.